Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro

Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro

Bibliographic Details
Main Author:	Wang, Hong
Language:	en_US
Published:	Nagoya University School of Medicine 2000
Subjects:	docetaxel (DOC) cisplatin (CDDP) non-small-cell lung cancer (NSCLC) combination chemotherapy isobologram cell cycle
Online Access:	http://hdl.handle.net/2237/5361

Similar Items

A randomized study of docetaxel plus cisplatin versus paclitaxel plus cisplatin in previously untreated advanced non-small cell lung cancer
by: Haiyong WANG, et al.
Published: (2008-02-01)

EFFECT OF CHEMOTHERAPY WITH DOCETAXEL / CISPLATIN ON GRANULOCYTIC HEMOPOIESIS IN PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA
by: V. E. Goldberg, et al.
Published: (2016-11-01)

Comparison of Chemotherapy Regiments between Cisplatin Etoposide and Cisplatin-Docetaxel on 2-Year and Progression-Free Survival in Late-Stage Non-Small Cell Lung Cancer Patients
by: Salman Paris Harahap, et al.
Published: (2016-06-01)

Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer
by: Celalettin Eroglu, et al.
Published: (2013-01-01)

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models
by: Coxon Angela, et al.
Published: (2012-09-01)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
by: Tsuneo Shimokawa, et al.
Published: (2021-01-01)

Study of a Molecular Promoter for Enhancing Cisplatin Cancer Chemotherapy
by: Nguyen, Jenny
Published: (2010)

Study of a Molecular Promoter for Enhancing Cisplatin Cancer Chemotherapy
by: Nguyen, Jenny
Published: (2010)

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer
by: Vinzenz Kroeber, et al.
Published: (2014-07-01)

Sequence-dependent Effect of Docetaxel with Gefitinib on the Proliferation  and Apoptosis of Lung Adenocarcinoma Cell H1975
by: Xinyu ZHANG, et al.
Published: (2012-03-01)

SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013-04-01)

Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients
by: Meiyu Fang, et al.
Published: (2012-09-01)

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview
by: S. Aishah A. Razak, et al.
Published: (2021-01-01)

Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters
by: Kuniaki Katsui, et al.
Published: (2020-07-01)

Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment
by: Yanyun Gao, et al.
Published: (2019-11-01)

The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
by: Jong Hyun Choi, M.D., et al.
Published: (2019-07-01)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
by: Moon Jin Kim, et al.
Published: (2019-09-01)

Cisplatin-based Chemotherapy in Elderly Patients with Non-small Cell Lung Cancer
by: Jian Li, et al.
Published: (2010-03-01)

Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus
by: Yukinori Yamagata, et al.
Published: (2020-09-01)

Cisplatin, Etoposide, and Vincristine Combination Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
by: SAITO, HIDEHIKO, et al.
Published: (1993)

Combination Chemotherapy of Lung Cancer – Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid–Polymer Hybrid Nanoparticles
by: Wu R, et al.
Published: (2020-06-01)

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
by: Jiangping Yang, et al.
Published: (2020-12-01)

OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013-12-01)

Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-small Cell Lung Cancer
by: Xingsheng HU, et al.
Published: (2012-10-01)

p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling
by: Yize Zhang, et al.
Published: (2019-07-01)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
by: Thierry Berghmans, et al.
Published: (2017-09-01)

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
by: Satoshi Ikeda, et al.
Published: (2018-03-01)

A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence
by: Qi Liu, et al.
Published: (2020-04-01)

Advance of second-line chemotherapy in advanced non-small cell lung cancer
by: Li ZHANG
Published: (2008-02-01)

The microneedles carrying cisplatin and IR820 to perform synergistic chemo-photodynamic therapy against breast cancer
by: Ji-jun Fu, et al.
Published: (2020-10-01)

The role of docetaxel in the multimodal treatment of non-small cell lung cancer
by: Rita De Sanctis, et al.
Published: (2009-06-01)

Gefitinib versus docetaxel in treated non-small-cell lung cancer: a meta-analysis
by: Wang Bing, et al.
Published: (2017-06-01)

Phenethyl Isothiocyanate and Cisplatin Co-Encapsulated in a Liposomal Nanoparticle for Treatment of Non-Small Cell Lung Cancer
by: Mengwei Sun, et al.
Published: (2019-02-01)

Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer
by: Ai D, et al.
Published: (2016-09-01)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
by: Xi-Lei Zhou, et al.
Published: (2021-05-01)

Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
by: Noriyuki Hirahara, et al.
Published: (2021-10-01)

Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer
by: Chia-En Chang, et al.
Published: (2018-01-01)

Docetaxel Toxicity Optimization in Esophageal Squamous Cell Carcinoma Cell Line YM-1: A Study of Cell Cycle and Doubling Time Effect
by: Boshra haghi, et al.
Published: (2021-03-01)

Screening and Identifying Cisplatin-Related Gene Mutations in Lung Squamous Cell Carcinoma
by: Li X, et al.
Published: (2020-12-01)

Esophagobronchial Fistula in a Patient with Squamous Cell Carcinoma of the Lung: A Case Report
by: Taichi Ozeki, et al.
Published: (2017-06-01)